| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
J. Biol. Chem., Vol. 260, Issue 21, 11574-11580, Sep, 1985
SP Bajaj, SI Rapaport and SL Maki
A murine monoclonal antibody (IgG1k, Kd approximately 10(-8) M) specific
for an epitope located on the heavy chain of human factor IXa was used to
study structure-function relationships of factor IX. The antibody inhibited
factor IX clotting activity but did not impair activation of factor IX
either by factor XIa/calcium or by factor VIIa/tissue factor/calcium. The
antibody also did not impair the binding of factor IXa to antithrombin III.
Moreover, the antibody did not prevent calcium and phospholipid (PL) from
inhibiting the binding of factor IXa to antithrombin III. The antibody also
failed to impair activation of factor VII by factor IXa/calcium/PL.
Furthermore, the antibody did not interfere with the very slow activation
of factor X by factor IXa/calcium/PL. In contrast, the antibody did
interfere with factor X activation when reaction mixtures also contained
factor VIII:Ca/von Willebrand factor. The marked acceleration of factor X
activation observed in control mixtures was not observed in mixtures
containing the antibody. Similar results were obtained in reaction mixtures
containing the Fab portion of the antibody and factor VIII:Ca free of von
Willebrand factor. In additional experiments, factor VIII:Ca/von Willebrand
factor was found to inhibit the binding of the antibody to 125I-factor IXa
as determined using an immunosorbent assay. Moreover, the antibody
displaced factor VIII:Ca from the factor X activator complex
(IXa/calcium/PL/VIII:Ca) as evidenced by an altered elution pattern on gel
filtration chromatography. From these observations, we conclude that the
antibody impairs the clotting activity of factor IXa through interference
with its binding of factor VIII:Ca. This suggests a significant role for
the heavy chain (residues of 181-415) of factor IXa in binding factor
VIII:Ca.
A monoclonal antibody to factor IX that inhibits the factor VIII:Ca potentiation of factor X activation
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  X. Yang, Y.-J. Chang, S.-W. Lin, and P. N. Walsh Identification of Residues Asn89, Ile90, and Val107 of the Factor IXa Second Epidermal Growth Factor Domain That Are Essential for the Assembly of the Factor X-activating Complex on Activated Platelets J. Biol. Chem., November 5, 2004; 279(45): 46400 - 46405. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Bates and J. I. Weitz Emerging Anticoagulant Drugs Arterioscler. Thromb. Vasc. Biol., September 1, 2003; 23(9): 1491 - 1500. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Shikamoto, T. Morita, Z. Fujimoto, and H. Mizuno Crystal Structure of Mg2+- and Ca2+-bound Gla Domain of Factor IX Complexed with Binding Protein J. Biol. Chem., June 20, 2003; 278(26): 24090 - 24094. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. R. Arruda, J. N. Hagstrom, J. Deitch, T. Heiman-Patterson, R. M. Camire, K. Chu, P. A. Fields, R. W. Herzog, L. B. Couto, P. J. Larson, et al. Posttranslational modifications of recombinant myotube-synthesized human factor IX Blood, January 1, 2001; 97(1): 130 - 138. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. I. Weitz and J. Hirsh New Anticoagulant Drugs Chest, January 1, 2001; 119(1_suppl): 95S - 107S. [Full Text] [PDF]
|
|
|
|
 |
|
 J. E. Ansell, J. I. Weitz, and A. J. Comerota Advances in Therapy and the Management of Antithrombotic Drugs for Venous Thromboembolism Hematology, January 1, 2000; 2000(1): 266 - 284. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Z. Feuerstein, A. Patel, J. R. Toomey, P. Bugelski, A. J. Nichols, W. R. Church, R. Valocik, P. Koster, A. Baker, and M. N. Blackburn Antithrombotic Efficacy of a Novel Murine Antihuman Factor IX Antibody in Rats Arterioscler. Thromb. Vasc. Biol., October 1, 1999; 19(10): 2554 - 2562. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Mathur and S. P. Bajaj Protease and EGF1 Domains of Factor IXa Play Distinct Roles in Binding to Factor VIIIa. IMPORTANCE OF HELIX 330 (HELIX 162 IN CHYMOTRYPSIN) OF PROTEASE DOMAIN OF FACTOR IXa IN ITS INTERACTION WITH FACTOR VIIIa J. Biol. Chem., June 25, 1999; 274(26): 18477 - 18486. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Lenting, J. A. van Mourik, and K. Mertens The Life Cycle of Coagulation Factor VIII in View of Its Structure and Function Blood, December 1, 1998; 92(11): 3983 - 3996. [Full Text] [PDF]
|
|
|
|
|
|
O. D. Christophe, P. J. Lenting, J. A. Kolkman, G. G. Brownlee, and K. Mertens Blood Coagulation Factor IX Residues Glu78 and Arg94 Provide a Link between Both Epidermal Growth Factor-like Domains That Is Crucial in the Interaction with Factor VIII Light Chain J. Biol. Chem., January 2, 1998; 273(1): 222 - 227. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Mathur, D. Zhong, A. K. Sabharwal, K. J. Smith, and S. P. Bajaj Interaction of Factor IXa with Factor VIIIa. EFFECTS OF PROTEASE DOMAIN Ca2+ BINDING SITE, PROTEOLYSIS IN THE AUTOLYSIS LOOP, PHOSPHOLIPID, AND FACTOR X J. Biol. Chem., September 12, 1997; 272(37): 23418 - 23426. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. M. O'Brien, L. V. Medved, and P. J. Fay Localization of Factor IXa and Factor VIIIa Interactive Sites J. Biol. Chem., November 10, 1995; 270(45): 27087 - 27092. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Lenting, H. t. Maat, P. P. F. M. Clijsters, M.-J. S. H. Donath, J. A. v. Mourik, and K. Mertens Cleavage at Arginine 145 in Human Blood Coagulation Factor IX Converts the Zymogen into a Factor VIII Binding Enzyme J. Biol. Chem., June 23, 1995; 270(25): 14884 - 14890. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |
